Cipla’s net profit for July to September was ₹878 crore, down 35% from ₹1,351 crore a year earlier. Revenue fell 2% to ₹7,404 crore.
The EBITDA margin fell to 18.7% from 25%, though it was 2 percentage points better than in the June quarter.
Where sales moved
India sales rose 12% to ₹3,516 crore, Cipla’s highest ever for a quarter. North America fell 19% to ₹1,643 crore. Bulk drugs and other sales fell 59%.
Cipla spent ₹423 crore on research, 5.7% of sales, and holds net cash of ₹9,823 crore.
